Clinical Trial

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of emraclidine following single oral administration of different immediate-release (IR) tablet formulations in healthy adult participants.
Protocol Amendment History 2 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-14
critical Recruitment opened 2026-06-16
Trial Details
NCT Number NCT07587008
Lead Sponsor AbbVie
Conditions Healthy Volunteers
Enrollment 12 participants
Start Date 2026-05-12
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-13